MX2020007293A - Compuestos desuterados, composiciones y metodos para tratar canceres asociados con la activacion etbr. - Google Patents

Compuestos desuterados, composiciones y metodos para tratar canceres asociados con la activacion etbr.

Info

Publication number
MX2020007293A
MX2020007293A MX2020007293A MX2020007293A MX2020007293A MX 2020007293 A MX2020007293 A MX 2020007293A MX 2020007293 A MX2020007293 A MX 2020007293A MX 2020007293 A MX2020007293 A MX 2020007293A MX 2020007293 A MX2020007293 A MX 2020007293A
Authority
MX
Mexico
Prior art keywords
methods
compounds
compositions
desuterated
treating cancers
Prior art date
Application number
MX2020007293A
Other languages
English (en)
Inventor
Sumayah Jamal
Original Assignee
Enb Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enb Therapeutics Inc filed Critical Enb Therapeutics Inc
Publication of MX2020007293A publication Critical patent/MX2020007293A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Aquí se describen compuestos deuterados, composiciones farmacéuticas de los mismos y métodos para tratar cánceres relacionados con ETBR. También se describe en el presente documento un sistema de administración para la liberación controlada y sistémica de al menos un antagonista de ETBR deuterado, opcionalmente junto con un agente anti oncológico adicional.
MX2020007293A 2018-01-12 2019-01-11 Compuestos desuterados, composiciones y metodos para tratar canceres asociados con la activacion etbr. MX2020007293A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862616729P 2018-01-12 2018-01-12
PCT/US2019/013377 WO2019140324A1 (en) 2018-01-12 2019-01-11 Deuterated compounds, compositions, and methods for treating cancers associated with etbr activation

Publications (1)

Publication Number Publication Date
MX2020007293A true MX2020007293A (es) 2021-01-08

Family

ID=67212721

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007293A MX2020007293A (es) 2018-01-12 2019-01-11 Compuestos desuterados, composiciones y metodos para tratar canceres asociados con la activacion etbr.

Country Status (10)

Country Link
US (4) US10435434B2 (es)
EP (1) EP3713571A4 (es)
JP (1) JP7539151B2 (es)
KR (1) KR102846292B1 (es)
CN (1) CN111886010A (es)
AU (1) AU2019206652B2 (es)
CA (1) CA3087009A1 (es)
EA (1) EA202091630A1 (es)
MX (1) MX2020007293A (es)
WO (1) WO2019140324A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6903055B2 (ja) 2015-08-03 2021-07-14 イーエヌビー・セラピューティクス・インク Ｅｔｂｒ活性化に関連した癌を治療するための組成物及び方法
JP7539151B2 (ja) 2018-01-12 2024-08-23 イーエヌビー・セラピューティクス・インク Ｅｔｂｒ活性化に関連する癌を処置するための重水素化化合物、組成物、および方法
WO2021011925A1 (en) * 2019-07-17 2021-01-21 Enb Therapeutics, Inc. Treatment of urothelial and kidney cancers by use of endothelin b receptor antagonists
TW202120486A (zh) * 2019-08-09 2021-06-01 英商阿帝歐斯製藥有限公司 新穎化合物
EP4608447A1 (en) * 2022-10-28 2025-09-03 ENB Therapeutics, Inc. Methods for treating cancers associated with etbr activation

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8705780D0 (en) * 1987-03-11 1987-04-15 Norsk Hydro As Anticancer compounds
US5496928A (en) 1990-06-07 1996-03-05 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic substance
TW217417B (es) 1991-12-04 1993-12-11 Manyu Seiyaku Kk
AU750245B2 (en) 1997-10-08 2002-07-11 Aurinia Phamaceuticals Inc. Deuterated cyclosporine analogs and their use as immunomodulating agents
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
GB0223854D0 (en) 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
CA2502848C (en) 2002-10-24 2012-10-02 The Board Of Trustees Of The University Of Illinois Use of irl-1620 and paclitaxel for preventing and treating breast tumors
US7713440B2 (en) 2003-10-08 2010-05-11 Lyotropic Therapeutics, Inc. Stabilized uncoated particles of reversed liquid crystalline phase materials
US8257918B2 (en) 2004-07-07 2012-09-04 The Regents Of The University Of California Intelligent nanomedicine integrating diagnosis and therapy
US20080102451A1 (en) 2006-10-31 2008-05-01 Abbott Laboratories Companion diagnostic assays for endothelin receptor antagonists
WO2008088727A2 (en) * 2007-01-12 2008-07-24 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US9289426B2 (en) 2007-03-21 2016-03-22 University Of Pennsylvania Methods and compositions for treating solid tumors and enhancing tumor vaccines
WO2008154585A1 (en) 2007-06-11 2008-12-18 Macdonald R Loch A drug delivery system for the prevention of cerebral vasospasm
CA2735421A1 (en) 2008-08-29 2010-03-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Delivery of a cd40 agonist to a tumor draining lymph node of a subject
US20110053968A1 (en) * 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
PT2464218E (pt) 2009-08-10 2015-09-16 Univ Texas Tratamento de metástases do cérebro com inibidores de recetores de endotelina, em combinação com um agente quimioterapêutico citotóxico
US20140341916A1 (en) 2011-10-28 2014-11-20 Genentech, Inc. Therapeutic combinations and methods of treating melanoma
TWI613215B (zh) 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
WO2013127004A1 (en) 2012-03-02 2013-09-06 The Governing Council Of The University Of Toronto Polymeric nanoparticles useful in theranostics
US20150182583A1 (en) 2012-08-06 2015-07-02 Board Of Regents, The University Of Texas System Methods for treatment and prevention of tauopathies by inhibiting endothelin receptors
WO2015095423A2 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
JP2017507900A (ja) 2013-12-17 2017-03-23 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法
WO2015110593A1 (en) * 2014-01-24 2015-07-30 Cecilia Naucler Use of endothelial receptor b inhibitors in prevention and treatment of human cytomegalovirus infection and cmv-related pathologies such as cardiovascular diseases and cancer
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
ES2835866T5 (es) 2015-05-12 2024-12-02 Hoffmann La Roche Procedimientos terapéuticos y de diagnóstico para el cáncer
AR105618A1 (es) 2015-05-29 2017-10-25 Genentech Inc Metilación del promotor del ligando al receptor de muerte programada (pd-l1) en cáncer
ES2789500T5 (es) 2015-05-29 2023-09-20 Hoffmann La Roche Procedimientos terapéuticos y de diagnóstico para el cáncer
JP6903055B2 (ja) 2015-08-03 2021-07-14 イーエヌビー・セラピューティクス・インク Ｅｔｂｒ活性化に関連した癌を治療するための組成物及び方法
JP6821693B2 (ja) 2016-02-29 2021-01-27 ジェネンテック， インコーポレイテッド がんのための治療方法及び診断方法
WO2017165491A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer
JP7539151B2 (ja) 2018-01-12 2024-08-23 イーエヌビー・セラピューティクス・インク Ｅｔｂｒ活性化に関連する癌を処置するための重水素化化合物、組成物、および方法
EP3746110A4 (en) 2018-03-30 2022-03-02 ENB Therapeutics, Inc. ETBR ANTAGONIST COMPOUNDS, COMPOSITIONS AND USES
WO2021011925A1 (en) 2019-07-17 2021-01-21 Enb Therapeutics, Inc. Treatment of urothelial and kidney cancers by use of endothelin b receptor antagonists
US20200289495A1 (en) 2020-03-24 2020-09-17 Enb Therapeutics, Inc. Methods of inhibiting endothelin b receptor expressing tumor metastases
US20200268829A1 (en) 2020-03-24 2020-08-27 Enb Therapeutics, Inc. Methods and compositions for inhibiting metastases of an endothelin b receptor expressing cancer

Also Published As

Publication number Publication date
US20210309694A1 (en) 2021-10-07
KR102846292B1 (ko) 2025-08-13
CN111886010A (zh) 2020-11-03
US20240360173A1 (en) 2024-10-31
US10435434B2 (en) 2019-10-08
US20190218251A1 (en) 2019-07-18
US12077604B2 (en) 2024-09-03
KR20200119246A (ko) 2020-10-19
WO2019140324A1 (en) 2019-07-18
AU2019206652A1 (en) 2020-07-16
US20190345197A1 (en) 2019-11-14
CA3087009A1 (en) 2019-07-18
JP2021510680A (ja) 2021-04-30
EA202091630A1 (ru) 2020-12-04
EP3713571A4 (en) 2021-08-25
US11066442B2 (en) 2021-07-20
EP3713571A1 (en) 2020-09-30
AU2019206652B2 (en) 2024-11-14
JP7539151B2 (ja) 2024-08-23

Similar Documents

Publication Publication Date Title
MX2020007293A (es) Compuestos desuterados, composiciones y metodos para tratar canceres asociados con la activacion etbr.
MX419719B (es) Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos.
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
SG10201902407PA (en) Injectable microparticles for hyper-localized release of therapeutic agents
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
ZA201902053B (en) Pharmaceutical composition
MX2018012486A (es) Composiciones para aplicacion topica de compuestos.
CL2018002727A1 (es) Medicina obtenida mediante la combinación de agonista fxr y arb
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
BR112018003985A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
MX2017016324A (es) Tratamientos de combinacion de antagonista de ligando 1 de muerte programada (pd-l1).
MX378281B (es) Conjugado farmaco-anticuerpo y su uso para el tratamiento contra el cancer.
BR112015018087A8 (pt) composto, composição farmacêutica e uso
BR112018002342A2 (pt) polímeros furtivos intrinsecamente desordenados e geneticamente modificados para entrega e métodos para uso dos mesmos
MX2018006800A (es) Composicion farmaceutica.
UY37800A (es) AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO
MX2017016524A (es) Sistemas de administracion para liberacion controlada de farmacos.
MX2024015576A (es) Tratamiento para migra?as
MX386732B (es) Composición farmacéutica de corticosteroide soluble.
MX387725B (es) Composición farmacéutica.
EP3442542A4 (en) NANOPARTICLE, DOSAGE FORM WITH CONTROLLED RELEASE, AND METHOD FOR RELEASING AN IMMUNOTHERAPEUTIC
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
MX2023006235A (es) Composiciones para administracion de farmacos y metodos de uso de las mismas.
EP3679608A4 (en) UPWARD CONVERSION SYSTEM FOR TRIPLET-TRIPLET ANNIHILATION AND COMPOSITIONS AND METHODS THEREOF FOR ACTIVE SUBSTANCE DELIVERY
CL2021001922A1 (es) Procedimientos para tratamiento de enfermedades con inhibidores de magl.